ACCESSIBILITY

24/7

Headlines

08:56

Reco.ai: Protecting your entire SaaS portfolio

08:53

S.F.L.: helping close education gaps with personalized plans

08:53

Coda: Turning spoken word into sign language

08:52

Bridgewise: Tracking the stock market using AI

Buzz

Most popular

Daily

Weekly

Oracle CEO: "If we continue on our current trajectory, reaching a valuation of a trillion dollars is inevitable"

Is your solitaire opponent actually a bot?

"The next phase for Miami will be an increase in exits"

Once $5 billion IPO bound, Cybereason merges with Trustwave amid decline

Cloudera acquires Israeli startup Octopai to advance metadata and AI integration

More news

Drugs

18 stories about Drugs

New CEO Steers Teva Back to Generics

28.11.17|Golan Hazani and Dror Reich

A reorganization plan announced by the company Monday would see the troubled drugmaker return to its core competencies, despite market pressures

Biomed Company Protalix to Lay Off a Fifth of its Workforce

26.11.17|Dror Reich

The Israel-based NYSE American-listed company is currently undergoing a streamlining process

Troubled Drugmaker Teva to Axe over 4,000 Jobs

23.11.17|Golan Hazani

Less than a month after stepping in as CEO, Kåre Schultz starts tightening the belt. The company is expected to oust Chief Scientific Officer Michael Hayden

Entera Bio Files for Nasdaq IPO

12.11.17|Lilach Baumer

The clinical stage company develops treatments mostly for osteoporosis and bone disorders

RedHill's Public Offering Spooks Investors, Sends Stock Down

09.11.17|Dror Reich

The Nasdaq-listed biopharmaceutical company priced its shares at $5.5 per American Depositary Share, a third of its 2015 public offering price, and dropped nearly 30% by Wednesday market close

Allergan Partners with Urine Incontinence Treatment Company

08.11.17|Lilach Baumer

Allergan is conducting clinical trials for a Botox-based bladder treatment, using a sustained release gel developed by Israel-based UroGen

Japanese NanoCarrier Partners with Cancer Treatment Company VBL Therapeutics

07.11.17|Dror Reich

The companies signed an exclusive licensing agreement in Japan for VBL's anti-cancer drug

New CEO to Take Helm at Troubled Teva Wednesday

31.10.17|Lilach Baumer

The generic drugmaker shed 67% of its market price over the last 12 months

Teva's Blockbuster Drug Takes Another Generic Blow

26.10.17|Lilach Baumer

Mylan and European Partner Synthon won U.K. patent case related to Teva's Copaxone

Teva Canada Probed by Ontario Government

23.10.17|Lilach Baumer

According to a report by Canadian newspaper Toronto Star the company is under investigation for alleged illegal rebates given to pharmacies to boost sales. A Teva spokesman said the company will cooperate fully with any investigation by the Ontario Ministry of Health.

מימין עודד ליברמן מנכל נוירודרם עם נציגי הרוכשת מיצובישי טנאבה

Mitsubishi Tanabe Pharma Finalizes $1.1 Billion Buy of Israel-Based NeuroDerm

19.10.17|Lilach Baumer

NeuroDerm is looking to bring major change to Parkinson patients with its drug reformulation

Kite Pharma’s Cancer Drug Gets Regulatory Nod

19.10.17|Lilach Baumer

The cancer-treatment company, bought by Gilead Science in August for $11.9 billion, will sell one treatment course of the drug for $373,000

Teva Sells Remaining Women's Health Assets

18.09.17|Lilach Baumer

After selling its Paragard business for $1.1 billion last week, Teva's remaining Women's Health business will be split between CVC Capital Partners and Foundation Consumer Healthcare in a $1.38 billion cash deal

IPO Hopeful Entera Bio Moves to Better Position

13.09.17|Dror Reich

Clinical-stage company Entera Bio develops pioneering technology for orphan disease hypoparathyroidism

The Ten Challenges Facing Teva's New CEO

12.09.17|Sophie Shulman

Kåre Schultz is the right man for the job, but he's facing multiple problems, from a changing market to a problematic board

Acne Cream Developer Sol-Gel files for $86 Million Nasdaq IPO

31.08.17|Dror Reich

The clinical-stage drug developer will remain a "controlled company" under current shareholder Arkin Dermatology

Anti-Acne Drug Developer Plans Nasdaq IPO

15.08.17|Golan Hazani

Sol-Gel approached potential underwriters. It aims to go public before the end of the year

מנכ"ל AstraZeneca פסקל סוריו Pascal Soriot

Teva in Talks to Appoint AstraZenca's Pascal Soriot as CEO

18.07.17|Golan Hazani

Mr. Soriot has met with the company’s search committee and its chairman and expressed his agreement to serve as its next CEO, people familiar with the matter said